Global stock markets on Monday and oil prices, leading to a sharp jump in the Tokyo stock market bright Japanese data helped offset concerns about a slowdown in China, and about the U.S. monetary stimulus will soon be withdrawn.
Japan's Nikkei average rose 1.3 percent to one-month high. N225 European shares rose 0.9 percent. FTEU3 investors in a positive atmosphere in the beginning of a new quarter. MSCI World stock index gains lifted MIWD00000PUS 0.3%.
Paying close attention to the central bank survey showed sentiment among Japanese manufacturers turned positive for the first time in nearly two years in June for three months. Data show that the recent market turmoil has not hurt by the government's policy of reflation positive emotions.
Plant data show that activity in June hit a nine month low, China's stock market recovery support mood ahead of the eurozone and the U.S. manufacturing sector's performance, since a similar survey in late Monday.
In the fixed income markets, the German government bond futures fell in early trade, continuing tensions over the Fed's plan, and with key non-farm payrolls report will be released on Friday to set the timing of the end of printing increased speculation.
"This week will be a huge bond short, if non-farm payrolls report confirms the Fed's decision to lower the unemployment rate forecast," JP Morgan Chase (JPMorgan) analyst said.
Brent crude oil futures prices fell before the low-$ 101.63 a barrel back to the Chinese data rose 9 cents to $ 102.25 a barrel.
Extensive stronger dollar this week, hitting four-week high of 99.55 yen against the Japanese. It also strengthened against the euro to $ 1.3010.
 



Other News:
Shares, oil bounce higher despite Fed concerns
Urban-rural alliance breaks down on farm bill vote
Publishers Random House, Penguin complete merger
Doctors: Patents keep HIV drugs too pricy to use
European officials slam US over bugging report
South Africa's Mandela still 'critical but stable'
Egypt erupts with protests demanding Morsi ouster
Onyx explores possible sale after rejecting Amgen offer